Concord Biotech acquires Celliimune to accelerate DNA-engineered cancer therapies
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
The trial, dubbed MALBEC, marks the first in a broader late-phase development push for MK-8748, with a second NVAMD study expected to begin later this year
The agreement will combine Biocytogen’s cutting-edge fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive drug development
Low-dose radiotherapy offers immediate pain relief, quicker recovery, and better movement through a non-invasive procedure
Its a major breakthrough for women’s ovarian cancer care in Europe
The approach, which could significantly reduce the number of rats used in certain dose-range finding studies
Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.
Government outlines advanced shared infrastructure and DBT-ICGEB biofoundry expansion to fast-track lab-to-market innovation across six strategic biotech sectors
Empowering 15 Women in STEM (Life Sciences) with scholarship, internship and mentorship
18-year veteran Saharsh will position the CDMO as a premier global API process development and commercial manufacturing specialist
Subscribe To Our Newsletter & Stay Updated